Regulatory 2023-08-31 | Ascelia Pharma significantly reduces organization to reach SPARKLE headline results PDF Report Presentation Webcast
Regulatory 2023-06-16 | Ascelia Pharma presented Orviglance Hepatic Impairment Data and hosted a Q&A with liver imaging experts at the 2023 ESGAR Annual Meeting PDF Report Presentation Webcast
Regulatory 2023-05-11 | QUARTERLY REPORT Q1 2023: Orviglance phase 3 study, SPARKLE, Last Patient Last Visit (LPLV) has been completed PDF Report Presentation Webcast
Regulatory 2023-05-04 | Bulletin from the Annual General Meeting in Ascelia Pharma AB on 4 May 2023 PDF Report Presentation Webcast
Regulatory 2023-04-03 | NOTICE OF ANNUAL GENERAL MEETING IN ASCELIA PHARMA AB PDF Report Presentation Webcast
Regulatory 2023-03-13 | Ascelia Pharma Mourns the Passing of Board Member René Spogárd PDF Report Presentation Webcast
Regulatory 2023-02-21 | Ascelia Pharma resolves on conversion of series C shares into ordinary shares for delivery to participants in incentive program PDF Report Presentation Webcast
Regulatory 2023-02-10 | QUARTERLY REPORT Q4 2022: Orviglance phase 3 study, SPARKLE, expected to be completed in Q1 2023. PDF Report Presentation Webcast
Regulatory 2022-12-02 | Nomination Committee appointed for AGM 2023 in Ascelia Pharma AB PDF Report Presentation Webcast
Regulatory 2022-11-04 | QUARTERLY REPORT Q3 2022: Successful completion of two out of three studies for regulatory submission PDF Report Presentation Webcast
Regulatory 2022-05-11 | Quarterly Report Q1 2022: Strong Orviglance support from healthcare professionals PDF Report Presentation Webcast
Regulatory 2022-05-05 | Bulletin from the Annual General Meeting in Ascelia Pharma AB on 5 May 2022 PDF Report Presentation Webcast
Regulatory 2022-04-05 | NOTICE OF ANNUAL GENERAL MEETING IN ASCELIA PHARMA AB PDF Report Presentation Webcast
Regulatory 2022-02-10 | Quarterly Report Q4 2021: Strong data for Orviglance vs. a gadolinium contrast agent PDF Report Presentation Webcast
Regulatory 2021-11-30 | Nomination Committee appointed for AGM 2022 in Ascelia Pharma AB PDF Report Presentation Webcast
Regulatory 2021-11-04 | Quarterly Report Q3 2021: Oncoral – entering clinical collaboration PDF Report Presentation Webcast
Regulatory 2021-05-12 | Quarterly Report Q1 2021: US office opened in preparation of launch PDF Report Presentation Webcast
Regulatory 2021-05-05 | Bulletin from the Annual General Meeting in Ascelia Pharma AB on 5 May 2021 PDF Report Presentation Webcast
